OraSure Technologies, Inc. (NASDAQ:OSUR) Position Increased by Systematic Financial Management LP

Systematic Financial Management LP lifted its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 33.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,673,609 shares of the medical instruments supplier's stock after acquiring an additional 421,497 shares during the quarter. Systematic Financial Management LP owned 2.24% of OraSure Technologies worth $6,042,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of OSUR. D. E. Shaw & Co. Inc. increased its holdings in OraSure Technologies by 180.5% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,517,541 shares of the medical instruments supplier's stock valued at $5,478,000 after buying an additional 976,475 shares in the last quarter. Renaissance Technologies LLC increased its holdings in OraSure Technologies by 23.1% during the 4th quarter. Renaissance Technologies LLC now owns 2,774,443 shares of the medical instruments supplier's stock valued at $10,016,000 after acquiring an additional 521,400 shares in the last quarter. Archon Capital Management LLC raised its position in OraSure Technologies by 145.1% during the fourth quarter. Archon Capital Management LLC now owns 827,777 shares of the medical instruments supplier's stock worth $2,988,000 after acquiring an additional 490,034 shares during the last quarter. Peapod Lane Capital LLC purchased a new stake in shares of OraSure Technologies in the fourth quarter valued at about $1,730,000. Finally, Jacobs Levy Equity Management Inc. grew its position in shares of OraSure Technologies by 76.5% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 926,608 shares of the medical instruments supplier's stock valued at $3,345,000 after purchasing an additional 401,658 shares during the last quarter. 93.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CFO Kenneth J. Mcgrath purchased 64,000 shares of the stock in a transaction on Thursday, February 27th. The stock was purchased at an average price of $3.15 per share, with a total value of $201,600.00. Following the completion of the transaction, the chief financial officer now owns 371,013 shares in the company, valued at approximately $1,168,690.95. The trade was a 20.85% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John P. Kenny acquired 47,659 shares of the business's stock in a transaction dated Thursday, February 27th. The stock was purchased at an average price of $3.17 per share, for a total transaction of $151,079.03. Following the completion of the acquisition, the director now owns 70,915 shares in the company, valued at approximately $224,800.55. This trade represents a 204.93% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 190,284 shares of company stock valued at $600,348. Insiders own 3.90% of the company's stock.

Analyst Ratings Changes

OSUR has been the topic of several recent research reports. Evercore ISI restated an "in-line" rating and issued a $3.00 price objective on shares of OraSure Technologies in a research report on Monday. Wall Street Zen upgraded shares of OraSure Technologies from a "sell" rating to a "hold" rating in a report on Saturday, May 17th.

OraSure Technologies Price Performance

OSUR stock traded down $0.04 during midday trading on Friday, hitting $2.54. The stock had a trading volume of 151,701 shares, compared to its average volume of 853,602. The company's 50-day moving average price is $3.01 and its 200 day moving average price is $3.52. The firm has a market cap of $189.62 million, a PE ratio of 16.83 and a beta of 0.42. OraSure Technologies, Inc. has a 12-month low of $2.36 and a 12-month high of $5.07.

OraSure Technologies announced that its board has initiated a stock repurchase program on Monday, March 24th that allows the company to repurchase $40.00 million in shares. This repurchase authorization allows the medical instruments supplier to reacquire up to 15.6% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's leadership believes its shares are undervalued.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.